CECP's CEO Investor Forum and Biopharma Sustainability Roundtable Release Report on Integrating Sustainability and Long-Term Planning for the Biopharma Sector
Research shows ESG performance is strongly predictive of long-term value creation and financial performance, when a sector-specific approach is maintained.
As the world begins to emerge from under the weight of multiple crises, investors are seeking more effective and efficient ESG (environment, social, and governance) communications directly from companies, which include a longer-term strategy and vision. Answering that call, Chief Executives for Corporate Purpose’s (CECP) CEO Investor Forum, an advisor that empowers CEOs on their journey to refocus investor expectations toward the long term, and the Biopharma Sustainability Roundtable (BSRT), a sector-specific collaboration platform that works with senior biotech and pharma executives to help drive their sustainability agendas forward, released a joint report on Integrating Sustainability and Long-Term Planning for the Biopharma Sector.
The new report, together with a companion practitioner’s guide, provide sector-specific tools for biopharma CEOs and their teams as they prepare sustainable Long-Term Plans to share with investors. Combining CECP’s Long-Term Plan framework and BSRT’s Biopharma Investor ESG Communications Guidance will help tailor content and perspective for the biopharma sector.
For more information and the full report, click here.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
